Table 2.
Key factors at the drug discontinuation of tofacitinib or methotrexate to achieve sustained low disease acitivity
| Variables | Discontinuation of tofacitinib (n=24) | Discontinuation of methotrexate (n=20) | ||||
| Sustained LDA | Non-sustained LDA | P value | Sustained LDA | Non-sustained LDA | P value | |
| n=10 | n=14 | n=13 | n=7 | |||
| Age (years) | 59.3 (12.4) | 57.4 (11.2) | 0·5383 | 57.5 (12.0) | 52.4 (16.3) | 0.6914 |
| Gender, n (% female) | 8 (80.0) | 14 (100.0) | 0.1630 | 12 (92.3) | 4 (57.1) | 0.1011 |
| Disease duration (month) | 52.9 (70.7) | 139.3 (110.6) | 0.0150 | 83.6 (85.4) | 106.0 (71.9) | 0.4509 |
| Steinbrocker’s classification, %, I/II/III/IV |
20/60/10/10 | 7/57/7/29 | 0.6144 | 23/54/8/15 | 29/29/13/29 | 0.7305 |
| Prior use of biologics | 4 (40.0%) | 13 (92.9%) | 0.0090 | 8 (61.5%) | 4 (57.1%) | 1.0000 |
| MTX use at baseline, n (%) | 10 (100.0%) | 14 (100.0%) | 1.0000 | 13 (100.0%) | 7 (100.0%) | 1.0000 |
| Dose, mg/week | 12.4±3.0 | 9.0±3.7 | 0.0243 | 12.0±3.7 | 14±2.3 | 0.2841 |
| Glucocorticoid use at baseline, n (%) | 0 (0.0%) | 2 (14.3%) | 0.4928 | 1 (7.7%) | 0 (0.0%) | 1.0000 |
| Dose, mg/day | 4.7 (0.3) | – | 2.5 | – | ||
| Tofacitinib dose /day, n (%) | 5 mg; 0 (0.0), 10 mg; 10 (100.0) | 5 mg; 1 (7.1), 10 mg; 10 (92.9) | 1.0000 | 5 mg; 3 (23.1), 10 mg; 10 (76.9) | 5 mg; 1 (14.3), 10 mg; 6 (85.7) | 1.0000 |
| 28-Tender joint count | 0.1 (0.3) | 0.2 (0.4) | 0.8160 | 0.0 (0.0) | 1.1 (1.5) | 0.0044 |
| 28-Swollen joint count | 0.1 (0.3) | 0.0 (0.0) | 1.0000 | 0.1 (0.3) | 0.3 (0.8) | 0.6344 |
| PGA, VAS 0–100 mm | 12.3 (20.4) | 10.1 (9.9) | 0.4084 | 9.0 (7.0) | 11.9 (9.2) | 0.9682 |
| EGA, VAS 0–100 mm | 3.4 (9.1) | 3.5 (5.2) | 0.1206 | 3.4 (6.0) | 4.7 (5.2) | 0.6252 |
| DAS28-ESR | 2.1 (0.3) | 2.3 (0.5) | 0.2309 | 2.1 (0.4) | 2.4 (0.6) | 0.2039 |
| CDAI | 1.0 (1.5) | 1.3 (0.9) | 0.2615 | 1.3 (0.7) | 2.0 (0.1) | 0.0269 |
| HAQ-DI | 0.2 (0.2) | 0.4 (0.4) | 0.0878 | 0.6 (0.7) | 0.5 (0.8) | 0.5466 |
| CRP (mg/dL) | 0.1 (0.2) | 0.1 (0.1) | 0.7376 | 0.1 (0.1) | 0.1 (0.1) | 0.4477 |
| ESR (mm/hour) | 19.9 (16.2) | 27.4 (19.6) | 0.1851 | 16.5 (8.1) | 16.6 (16.7) | 0.3734 |
| Rheumatoid factor (U/mL) | 50.1 (60.3) | 128.1 (144.6) | 0.0404 | 46.3 (64.2) | 72.6 (115.5) | 0.8205 |
| Rheumatoid factor positive, n (%) | 7 (70.0) | 12 (85.7) | 0.3500 | 5 (38.5) | 4 (57.1) | 0.4231 |
| Anti-CCP antibody (U/mL) | 22.2 (33.0) | 230.5 (547.2) | 0.0508 | 250.4 (498.7) | 82.1 (135.4) | 0.2212 |
| Anti-CCP antibody positive, n (%) | 5 (50.0) | 13 (92.9) | 0.0168 | 8 (61.5) | 4 (57.1) | 0.8482 |
| MMP-3 (ng/mL) | 58.8 (28.4) | 50.4 (31.4) | 0.1602 | 45.2 (12.7) | 47.3 (21.6) | 0.8919 |
Data reported as mean (SD).
CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score 28 Joint; EGA, Evaluator’s Global Assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LDA, low disease acitivity; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, Patient’s Global Assessment.